Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15001859 | 0.96 | MEN1 (0.44) | MEN1NAMPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15001867 | 0.87 | SMN1; SMN2 (0.53) | MEN1SMN1; SMN2ALDH1A1TSHRPOLB | |
| SCHEMBL15001856 | 0.85 | SMN1; SMN2 (0.44) | MEN1SMN1; SMN2ALDH1A1TSHRPOLB | |
| SCHEMBL15001838 | 0.83 | SMN1; SMN2 (0.42) | MEN1SMN1; SMN2ALDH1A1TSHRPOLB | |
| SCHEMBL15001846 | 0.83 | ESR1 (0.48) | MEN1SMN1; SMN2ALDH1A1TSHRMAPT | |
| SCHEMBL15001850 | 0.81 | KMT2A (0.48) | MEN1SMN1; SMN2ALDH1A1POLBKMT2A | |
| SCHEMBL15001940 | 0.80 | KMT2A (0.62) | MEN1ALDH1A1TSHRPOLBKMT2A | |
| SCHEMBL15001863 | 0.79 | KDM4E (0.44) | MEN1SMN1; SMN2ALDH1A1TSHRMAPT | |
| SCHEMBL15001835 | 0.79 | TAAR1 (0.47) | MEN1SMN1; SMN2ALDH1A1TSHRMAPT | |
| SCHEMBL15001837 | 0.77 | SMN1; SMN2 (0.41) | MEN1SMN1; SMN2ALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741892-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143870-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | MEN1 4793/4885NAMPT 3856/4885SMN1; SMN2 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.